Allena Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. was a United States biopharmaceutical company headquartered in Newton, Massachusetts, and associated with a U.S. public-market listing on the Nasdaq/NYSE universe as reflected in SEC filings. For French-, Belgian- and Swiss-based investors, the company belongs in the Health & Pharma bucket, more specifically in specialty biotechnology. Based on SEC disclosures, Allena was formed to discover, develop, and commercialize first-in-class oral enzyme therapeutics targeting rare and severe metabolic and kidney disorders. The company’s core scientific identity was therefore highly focused rather than diversified, with a business model typical of clinical-stage biotech: build a pipeline, generate clinical data, seek regulatory alignment, and only later attempt commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1624658/000156459020010991/alna-10k_20191231.htm?utm_source=openai)) Allena’s best-known asset was reloxaliase, an oral enzyme therapeutic intended to reduce intestinal oxalate absorption and thereby address hyperoxaluria, a metabolic disorder linked to kidney stones, chronic kidney disease, and other serious renal complications. This positioned the company in a very specialized niche with a clearly defined unmet medical need. Strategically, the appeal of the asset was its oral administration and its potential to deliver a differentiated mechanism of action in a rare-disease setting. In competitive terms, Allena was not a broad-platform pharmaceutical company; it was a focused development-stage player whose valuation depended heavily on clinical efficacy, safety, and regulatory progress. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1624658/000119312519286673/d831178dex991.htm?utm_source=openai)) The SEC record also points to additional development programs, including URIROX-1 and URIROX-2, reinforcing the conclusion that Allena’s business was centered on R&D execution rather than commercial scale. The company’s geographic footprint was primarily U.S.-based, with headquarters in Newton, Massachusetts, United States. Its operating history and investor materials indicate a financing base typical of specialist biotech companies supported by experienced healthcare investors rather than a large diversified pharmaceutical balance sheet. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1624658/000119312517305872/d431688ds1.htm?utm_source=openai)) As for recent developments, the available SEC-linked materials mainly highlight clinical-program communication around reloxaliase and related trials, rather than evidence of a broad commercial franchise. That is an important distinction for investors: Allena should be viewed as a high-risk, event-driven biotech story, where the main value drivers were pipeline data, regulatory interactions, and funding capacity, not established product revenues. In short, the company’s market profile was that of a small U.S. clinical-stage biotechnology issuer listed in the Nasdaq/NYSE ecosystem, with upside tied to a narrow set of specialized renal/metabolic programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1624658/000119312519286673/d831178dex991.htm?utm_source=openai))